OTLC

Oncotelic Therapeutics Inc

It&#8217;s not often that a micro-cap company with a market value of around $40 million announces a third-party valuation of its drug development pipeline at $1.7 billion, 45% of which it owns. But that&#8217;s exactly what was revealed in a press release this morning. As expected, the stock reacted swiftly and rallied on the news.</p></p>As mentioned, shares of Oncotelic Therapeutics <a href="https://www.allpennystocks.com/stockquote/OTLC" target="_blank"><strong>(OTCQB: OTLC)</strong></a> are surging on news that the company announced a major milestone after its joint venture partner, GMP Bio, completed an independent third-party valuation of its drug development pipeline. The assessment, performed by Frost &amp; Sullivan (Hong Kong), values the pipeline at roughly $1.7 billion, translating to an estimated $765 million potential value for Oncotelic based on its 45% ownership stake. The company noted that this figure is forward-looking and non-binding, and it does not reflect fair value under U.S. GAAP. To support upcoming financial disclosures, a separate ASC-compliant valuation is already underway. If that analysis indicates a materially higher carrying value, Oncotelic may adjust future financial statements to reflect its increased minority interest, potentially boosting total assets and shareholder equity, pending the outcome of the review and applicable accounting standards.</p></p>The joint venture has made significant progress across its therapeutic programs, including moving OT-101 into a Phase 3 PDAC trial and multiple Phase 2 combination studies. Meanwhile, GMP Bio is actively expanding its Deciparticle&#8482; nanomedicine platform, with several candidates advancing toward clinical development. Its San Diego GMP-licensed manufacturing facility is now fully operational and ready to support upcoming trials. Looking ahead, the JV is exploring a possible IPO on the Hong Kong Stock Exchange targeted for late 2026. While market conditions and regulatory approval will ultimately dictate the timing, Oncotelic views the strong pipeline valuation as a key indicator of the strategic value behind the potential offering.</p></p>&#8220;This represents one of the most significant milestones in Oncotelic&#8217;s history,&#8221; said Dr. Vuong Trieu, Chief Executive Officer of Oncotelic Therapeutics. &#8220;The independent valuation recognizes the multi-year scientific and clinical progress achieved through our GMP Bio joint venture and affirms the long-term potential of OT-101 and our Deciparticle&#8482; nanomedicine platform.&#8221;</p></p>Shares of OTLC are currently trading up 26.15% at $0.09524 in mid-morning trading.</p> <p>Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.</p><p>View <a href='https://www.allpennystocks.com/specialreportsUS/4012/micro-cap-stuns-market-with-billion-dollar-pipeline-valuation'>more of this article</a> on AllPennyStocks.com.</p><p><strong>About AllPennyStocks.com Media, Inc.:</strong></p> <p>Founded in 1999, AllPennyStocks.com Media, Inc. is North America's largest and longest running website dedicated exclusively to micro-cap and small-cap insights.</p> <p>Catering to both Canadian and U.S. markets, AllPennyStocks.com provides a wealth of resources and expert content designed for everyone, from beginner investors to seasoned traders.</p> <p>AllPennyStocks.com's content is prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals.</p> <p>Contact:</p> <p>AllPennyStocks.com Media, Inc.</p> <p>Email: <a href="mailto:ads@allpennystocks.com">ads@allpennystocks.com</a></p> <p>Phone: (800) 558-4560 Ext: 101</p>